IM CANNABIS CORP (IMCC) Stock Fundamental Analysis
USA - NASDAQ:IMCC - CA44969Q4060 - Common Stock
1.01 USD
-0.23 (-18.55%)
Taking everything into account, IMCC scores 3 out of 10 in our fundamental rating. IMCC was compared to 192 industry peers in the Pharmaceuticals industry. Both the profitability and financial health of IMCC have multiple concerns. While showing a medium growth rate, IMCC is valued expensive at the moment.
1. Profitability
1.1 Basic Checks
In the past year IMCC has reported negative net income.
IMCC had a positive operating cash flow in the past year.
IMCC had negative earnings in each of the past 5 years.
IMCC had a negative operating cash flow in each of the past 5 years.
1.2 Ratios
Looking at the Return On Assets, with a value of -10.43%, IMCC is in the better half of the industry, outperforming 66.15% of the companies in the same industry.
With a Return On Equity value of -88.04%, IMCC perfoms like the industry average, outperforming 43.75% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -10.43% | ||
| ROE | -88.04% | ||
| ROIC | N/A |
ROA(3y)-119.26%
ROA(5y)-87.85%
ROE(3y)-367.14%
ROE(5y)-273.77%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
IMCC has a Gross Margin (18.58%) which is in line with its industry peers.
IMCC's Gross Margin has improved in the last couple of years.
The Profit Margin and Operating Margin are not available for IMCC so they could not be analyzed.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 18.58% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y497.26%
GM growth 5YN/A
2. Health
2.1 Basic Checks
IMCC does not have a ROIC to compare to the WACC, probably because it is not profitable.
IMCC has more shares outstanding than it did 1 year ago.
Compared to 5 years ago, IMCC has more shares outstanding
Compared to 1 year ago, IMCC has a worse debt to assets ratio.
2.2 Solvency
Based on the Altman-Z score of -7.30, we must say that IMCC is in the distress zone and has some risk of bankruptcy.
IMCC has a worse Altman-Z score (-7.30) than 64.06% of its industry peers.
The Debt to FCF ratio of IMCC is 4.09, which is a neutral value as it means it would take IMCC, 4.09 years of fcf income to pay off all of its debts.
IMCC has a better Debt to FCF ratio (4.09) than 84.38% of its industry peers.
IMCC has a Debt/Equity ratio of 2.52. This is a high value indicating a heavy dependency on external financing.
IMCC has a worse Debt to Equity ratio (2.52) than 79.69% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 2.52 | ||
| Debt/FCF | 4.09 | ||
| Altman-Z | -7.3 |
ROIC/WACCN/A
WACC12.09%
2.3 Liquidity
IMCC has a Current Ratio of 0.72. This is a bad value and indicates that IMCC is not financially healthy enough and could expect problems in meeting its short term obligations.
IMCC's Current ratio of 0.72 is on the low side compared to the rest of the industry. IMCC is outperformed by 90.10% of its industry peers.
IMCC has a Quick Ratio of 0.72. This is a bad value and indicates that IMCC is not financially healthy enough and could expect problems in meeting its short term obligations.
With a Quick ratio value of 0.59, IMCC is not doing good in the industry: 88.02% of the companies in the same industry are doing better.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 0.72 | ||
| Quick Ratio | 0.59 |
3. Growth
3.1 Past
IMCC shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -78.84%.
IMCC shows quite a strong growth in Revenue. In the last year, the Revenue has grown by 10.71%.
IMCC shows quite a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 16.64% yearly.
EPS 1Y (TTM)-78.84%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%58.09%
Revenue 1Y (TTM)10.71%
Revenue growth 3Y16.64%
Revenue growth 5YN/A
Sales Q2Q%-14.29%
3.2 Future
IMCC is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 36.54% yearly.
Based on estimates for the next years, IMCC will show a very strong growth in Revenue. The Revenue will grow by 26.24% on average per year.
EPS Next Y86.24%
EPS Next 2Y36.54%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next Year41.23%
Revenue Next 2Y26.24%
Revenue Next 3YN/A
Revenue Next 5YN/A
3.3 Evolution
When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
4. Valuation
4.1 Price/Earnings Ratio
IMCC reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Also next year IMCC is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
Compared to the rest of the industry, the Price/Free Cash Flow ratio of IMCC indicates a rather cheap valuation: IMCC is cheaper than 98.96% of the companies listed in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 1.93 | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
A more expensive valuation may be justified as IMCC's earnings are expected to grow with 36.54% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y36.54%
EPS Next 3YN/A
5. Dividend
5.1 Amount
IMCC does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
NASDAQ:IMCC (11/17/2025, 10:04:14 AM)
1.01
-0.23 (-18.55%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)
Earnings (Next)
Inst Owners4.31%
Inst Owner Change-14.31%
Ins Owners44.66%
Ins Owner ChangeN/A
Market Cap5.30M
Revenue(TTM)54.03M
Net Income(TTM)-4.69M
Analysts82.86
Price TargetN/A
Short Float %0.42%
Short Ratio0.02
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)0
Avg Revenue beat(2)-17.69%
Min Revenue beat(2)-25.65%
Max Revenue beat(2)-9.73%
Revenue beat(4)1
Avg Revenue beat(4)-9.56%
Min Revenue beat(4)-25.65%
Max Revenue beat(4)9.9%
Revenue beat(8)3
Avg Revenue beat(8)-4.84%
Revenue beat(12)3
Avg Revenue beat(12)-9.88%
Revenue beat(16)5
Avg Revenue beat(16)-5.1%
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)0%
EPS NQ rev (3m)0%
EPS NY rev (1m)0%
EPS NY rev (3m)0%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)0%
Revenue NY rev (1m)0%
Revenue NY rev (3m)0%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | 0.14 | ||
| P/FCF | 1.93 | ||
| P/OCF | 1.85 | ||
| P/B | 1.4 | ||
| P/tB | N/A | ||
| EV/EBITDA | N/A |
EPS(TTM)-2.41
EYN/A
EPS(NY)-0.33
Fwd EYN/A
FCF(TTM)0.52
FCFY51.93%
OCF(TTM)0.55
OCFY54.01%
SpS7.4
BVpS0.72
TBVpS-0.57
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -10.43% | ||
| ROE | -88.04% | ||
| ROCE | N/A | ||
| ROIC | N/A | ||
| ROICexc | N/A | ||
| ROICexgc | N/A | ||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 18.58% | ||
| FCFM | 7.09% |
ROA(3y)-119.26%
ROA(5y)-87.85%
ROE(3y)-367.14%
ROE(5y)-273.77%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y497.26%
GM growth 5YN/A
F-Score7
Asset Turnover1.21
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 2.52 | ||
| Debt/FCF | 4.09 | ||
| Debt/EBITDA | N/A | ||
| Cap/Depr | 7.98% | ||
| Cap/Sales | 0.28% | ||
| Interest Coverage | N/A | ||
| Cash Conversion | N/A | ||
| Profit Quality | N/A | ||
| Current Ratio | 0.72 | ||
| Quick Ratio | 0.59 | ||
| Altman-Z | -7.3 |
F-Score7
WACC12.09%
ROIC/WACCN/A
Cap/Depr(3y)15.95%
Cap/Depr(5y)83.89%
Cap/Sales(3y)1.45%
Cap/Sales(5y)6.98%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-78.84%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%58.09%
EPS Next Y86.24%
EPS Next 2Y36.54%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)10.71%
Revenue growth 3Y16.64%
Revenue growth 5YN/A
Sales Q2Q%-14.29%
Revenue Next Year41.23%
Revenue Next 2Y26.24%
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y66.12%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year130.87%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y136.6%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y143.37%
OCF growth 3YN/A
OCF growth 5YN/A
IM CANNABIS CORP / IMCC FAQ
What is the fundamental rating for IMCC stock?
ChartMill assigns a fundamental rating of 3 / 10 to IMCC.
What is the valuation status for IMCC stock?
ChartMill assigns a valuation rating of 2 / 10 to IM CANNABIS CORP (IMCC). This can be considered as Overvalued.
Can you provide the profitability details for IM CANNABIS CORP?
IM CANNABIS CORP (IMCC) has a profitability rating of 2 / 10.
Can you provide the expected EPS growth for IMCC stock?
The Earnings per Share (EPS) of IM CANNABIS CORP (IMCC) is expected to grow by 86.24% in the next year.